GLP-1 patches for weight loss have made the scene—but a leading MD warns you they aren't the same as the more familiar prescriptions.

showing that they could predict which obese people were likely to respond better to liraglutide — the GLP-1 agonist in Victoza, which resembles the GLP-1 agonists in Wegovy and Mounjaro — and ...

They compared patients prescribed GLP-1-RAs or SGLT2 inhibitors with 68,400 patients prescribed DPP-4 inhibitors, which previous studies suggest do not increase ARD risk.

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are no longer considered to officially be in shortage.

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...

Wilding says that the presence of GLP-1 receptors in the brain is thought to be one of the key reasons why GLP-1 drugs can impact hunger, fullness and reward, as they allow these drugs to ...

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not one-size-fits-all all. Dr. Noor Khan, from UPMC, helped us understand more about ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ...

The analysis found that obesity-related cancer occurred in 150 of 3,178 surgery patients (5.76 cases per 1,000 person-years) and in 148 of 3,178 patients taking GLP-1s (5.64 cases per 1,000 person ...

Between 168 patients in the GLP-1 agonist groups and 169 control patients, the mean difference in post-cessation weight gain was -2.59 kg (95% CI -3.70 t0 -1.48, P <0.00001).